PMID- 37246910
OWN - NLM
STAT- MEDLINE
DCOM- 20230531
LR  - 20230531
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 34
IP  - 1
DP  - 2023 Dec
TI  - Occurrence of adverse events associated with the initiation of methotrexate and 
      biologics for the treatment of psoriasis in routine clinical practice.
PG  - 2215354
LID - 10.1080/09546634.2023.2215354 [doi]
AB  - Background: Limited information exists on the risk of adverse events (AEs) 
      attributed to methotrexate (MTX) and biologics for the treatment of 
      psoriasis/psoriatic arthritis (PsA/PsO) in heterogeneous clinical practice and 
      beyond the duration of clinical trials.Methods: An observational study of 6294 
      adults with incident PsA/PsO who initiated MTX or biologics in Stockholm from 
      2006-2021 was conducted. The risk of kidney, liver, hematological, serious 
      infectious, and major gastrointestinal AEs was quantified and compared between 
      therapies using incidence rates, absolute risks, and adjusted hazard ratios (HRs) 
      from propensity-score weighted Cox regression.Results: Median follow-up was 4.3 
      (2-7) years. Users of MTX had a higher risk of anemia (HR 1.79 [95% CI, 
      1.48-2.16]), particularly mild-moderate anemias (1.93;1.49-2.50), and mild 
      (1.46;1.03-2.06) and moderate-severe liver AEs (2.22;1.19-4.15) compared to 
      biologics. Chronic kidney disease incidence did not differ between therapies 
      (affecting 1.5% of the population in 5 years; HR:1.03;0.48-2.22). Acute kidney 
      injury, serious infections, and major gastrointestinal AEs showed low absolute 
      risks and no clinically meaningful differences between both therapies.Conclusion: 
      The use of MTX for psoriasis patients in routine care was associated with a 
      higher risk of anemia and liver AEs than biologics, but similar risks of kidney, 
      serious infections, and major gastrointestinal AEs.
FAU - Mazhar, Faizan
AU  - Mazhar F
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Krantz, Asa
AU  - Krantz A
AD  - Dermatology and Venereology Section, Department of Medicine Solna, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Schalin, Lovisa
AU  - Schalin L
AD  - Epidemiology, Amgen, Denmark.
FAU - Lysell, Josefin
AU  - Lysell J
AD  - Dermatology and Venereology Section, Department of Medicine Solna, Karolinska 
      Institutet, Stockholm, Sweden.
AD  - Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Carrero, Juan Jesus
AU  - Carrero JJ
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Division of Nephrology, Department of Clinical Sciences, Karolinska Institutet, 
      Danderyd Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Methotrexate/adverse effects
MH  - *Biological Products/adverse effects
MH  - *Arthritis, Psoriatic/drug therapy
MH  - *Psoriasis/drug therapy/chemically induced
MH  - Cognition
OTO - NOTNLM
OT  - adverse events
OT  - biologics
OT  - methotrexate
OT  - psoriasis
OT  - safety
EDAT- 2023/05/29 13:04
MHDA- 2023/05/31 06:41
CRDT- 2023/05/29 09:23
PHST- 2023/05/31 06:41 [medline]
PHST- 2023/05/29 13:04 [pubmed]
PHST- 2023/05/29 09:23 [entrez]
AID - 10.1080/09546634.2023.2215354 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2023 Dec;34(1):2215354. doi: 10.1080/09546634.2023.2215354.